Show
Sort by
-
- Journal Article
- open access
Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease
-
Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data
-
- Journal Article
- A1
- open access
Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression : results from the SORAYA study
-
Outcomes of childhood noninfant acute lymphoblastic leukemia with 11q23/KMT2A rearrangements in a modern therapy era : a retrospective international study
-
- Journal Article
- A1
- open access
Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia : a study by the International Berlin-Frankfurt-Münster Study Group
-
Reply to Z.R. McCaw et al
-
- Journal Article
- A1
- open access
Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer : placebo-controlled randomized phase III ATALANTE/ENGOT-ov29 trial
-
- Journal Article
- A1
- open access
Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer : results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
-
Short and medium-term outcomes of patients with solid cancer hospitalized with COVID-19 in Belgium according to cancer diagnosis and treatment characteristics
-
Subcutaneous epcoritamab plus R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT) : preliminary phase 1/2 results
-
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy : CARTITUDE-2, cohort B
-
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior therapies : pivotal phase II expansion results
-
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL) : phase 1/2 data update
-
- Conference Paper
- C3
- open access
Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma : a BEACON-Neuroblastoma biomarker study
-
- Conference Paper
- C3
- open access
KEYNOTE-B79 phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients
-
- Journal Article
- A1
- open access
Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis
-
- Journal Article
- A1
- open access
Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial
-
- Journal Article
- A1
- open access
Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer : analysis of STOMP and ORIOLE trials
-
- Journal Article
- A1
- open access
Combining Ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenstrom's macroglobulinemia : final analysis of the phase I/II HOVON124/ECWM-R2 study
-
- Journal Article
- A1
- open access
The critical role of academic clinical trials in pediatric cancer drug approvals : design, conduct, and fit for purpose data for positive regulatory decisions